Fentaw Zinabu, Molla Assresie, Wedajo Shambel, Mebratu Wondwosen
School of Public Health, Wollo University College of Medicine and Health Science, Dessie, Amhara Region, Ethiopia.
HIV AIDS (Auckl). 2020 Nov 17;12:749-756. doi: 10.2147/HIV.S267629. eCollection 2020.
Virological failure is defined as having viral load measurement greater or equal to 1000 copies/mm after at least six-month exposure to antiretroviral therapy. According to the Joint United Nations Programme on HIV/AIDS (UNAIDS-2018) report, globally nearly one in five patients on first-line antiretroviral therapy had experienced virological failure. In line with this, Ethiopia federal ministry of health also reported that one in four patients had experienced virological failure in the year 2016. To date, very little is known about the predictors of virological failure in the local context. Therefore, this study intended to address the determinants of virological failure among patients on a first-line antiretroviral regimen.
A case-control study was conducted among clients on first-line antiretroviral therapy in Amhara regional state, January 2019 with a sample of 257 clients; of these, 86 clients were cases. Data were collected via patient interview and chart extraction for clinical profiles using standardized tools. Binary logistic regression was computed to identify the determinants of virological failure using Stata version 14 and the result was displayed using adjusted odds ratio with a 95% confidence interval.
Out of the proposed samples, 255 clients were considered for final analysis. The odds of virological failure are higher among poor medication adherence (AOR: 10.2:95% CI [4.1-25.8]), age<35 years (AOR: 3.07 95% CI 1.4-6.8), low baseline CD4 (AOR 3.9: 95% CI 1.6-9.6), and Khat chewers (AOR: 9.5:95% CI 2.8-32.4) as compared with their counterparts.
Being a young age, poor immunity at the initiation of antiretroviral, Khat chewer, and poor medication adherence significantly associated with virological failure.
病毒学失败被定义为在接受抗逆转录病毒治疗至少六个月后,病毒载量测量值大于或等于1000拷贝/立方毫米。根据联合国艾滋病规划署(UNAIDS - 2018)的报告,全球近五分之一接受一线抗逆转录病毒治疗的患者经历过病毒学失败。与此一致的是,埃塞俄比亚联邦卫生部也报告称,2016年有四分之一的患者经历过病毒学失败。迄今为止,在当地背景下,关于病毒学失败的预测因素知之甚少。因此,本研究旨在探讨接受一线抗逆转录病毒治疗方案的患者中病毒学失败的决定因素。
2019年1月,在阿姆哈拉州对接受一线抗逆转录病毒治疗的患者进行了一项病例对照研究,样本为257名患者;其中86名患者为病例组。通过患者访谈和使用标准化工具提取病历以获取临床资料来收集数据。使用Stata 14版计算二元逻辑回归以确定病毒学失败的决定因素,并使用调整后的比值比及95%置信区间展示结果。
在拟定的样本中,255名患者被纳入最终分析。与对照组相比,药物依从性差(调整后的比值比:10.2;95%置信区间[4.1 - 25.8])、年龄<35岁(调整后的比值比:3.07;95%置信区间1.4 - 6.8)、基线CD4水平低(调整后的比值比3.9;95%置信区间1.6 - 9.6)以及咀嚼恰特草者(调整后的比值比:9.5;95%置信区间2.8 - 32.4)发生病毒学失败的几率更高。
年龄小、开始抗逆转录病毒治疗时免疫力差、咀嚼恰特草以及药物依从性差与病毒学失败显著相关。